Log in to search using one of your social media accounts:

 

Prostate Cancer Screening.
Abstract During the prostate-specific antigen-based prostate cancer (PCa) screening era there has been a 53% decrease in the US PCa mortality rate. Concerns about overdiagnosis and overtreatment combined with misinterpretation of clinical trial data led to a recommendation against PCa screening, resulting in a subsequent reversion to more high-risk disease at diagnosis. Re-evaluation of trial data and increasing acceptance of active surveillance led to a new draft recommendation for shared decision making for men aged 55 to 69 years old. Further consideration is needed for more intensive screening in men with...
Source: Clinical Prostate Cancer - February 7, 2018 Category: Cancer & Oncology Authors: Catalona WJ Tags: Med Clin North Am Source Type: research

Prostate Cancer: A Contemporary Approach to Treatment and Outcomes.
Abstract Given the high incidence of prostate cancer and the need for shared decision-making before screening, it is imperative that primary care providers understand treatment options and treatment adverse effects. In this review article, the treatment options for the localized and metastatic prostate cancer are discussed, including the different modalities and their indications, adverse effects, oncologic outcomes, posttreatment monitoring, and potential treatment options following cancer recurrence. PMID: 29406054 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 7, 2018 Category: Cancer & Oncology Authors: Weiner AB, Kundu SD Tags: Med Clin North Am Source Type: research

Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?
PMID: 29401003 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 5, 2018 Category: Cancer & Oncology Authors: Faiena I, Holden S, Cooperberg MR, Holden S, Soule HR, Simons JW, Morgan TM, Penson DF, Morgans AK, Hussain M Tags: J Clin Oncol Source Type: research

Circulating vitamin D concentration and risk of prostate cancer: a dose-response meta-analysis of prospective studies.
Conclusion: The findings suggest that highest 25[OH]D concentration is correlated with elevated risk of prostate cancer and a modest dose-response effect exists in this association; however, more studies are needed. PMID: 29386901 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 3, 2018 Category: Cancer & Oncology Authors: Gao J, Wei W, Wang G, Zhou H, Fu Y, Liu N Tags: Ther Clin Risk Manag Source Type: research

Re-Creating the Urinary Tract: An Art Derived from Science.
PMID: 29169455 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - November 26, 2017 Category: Cancer & Oncology Authors: Taneja SS Tags: Urol Clin North Am Source Type: research

Effective Prostate-Specific Membrane Antigen-Based 18F-DCFPyL-Guided Cryoablation of a Single Positive Site in a Patient Believed to Be More Metastatic on 11C-Choline PET/CT.
Abstract PET/CT-guided interventions using specific radiotracers are promising for detecting avid lesions not well visualized with other imaging methods. A 72-year-old man who initially presented with prostate cancer Gleason 5 + 4 (prostate-specific antigen [PSA] = 7.9 ng/mL) underwent radical prostatectomy and node dissection. Three years after radiation, a rising PSA was observed over 6 months with PSA level reaching 1.08 ng/mL. He was evaluated with prostate-specific membrane antigen-based (PSMA) F-DCFPyL PET/CT, conventional CT, F-FDG PET/CT, and C-choline PET/CT. The PSMA F-DCFPyL PET/CT successfully targeted...
Source: Clinical Prostate Cancer - November 5, 2017 Category: Cancer & Oncology Authors: Cornelis FH, Durack JC, Morris MJ, Scher HI, Solomon SB Tags: Clin Nucl Med Source Type: research

Significance of long chain polyunsaturated fatty acids in human health.
odríguez C Abstract In the last decades, the development of new technologies applied to lipidomics has revitalized the analysis of lipid profile alterations and the understanding of the underlying molecular mechanisms of lipid metabolism, together with their involvement in the occurrence of human disease. Of particular interest is the study of omega-3 and omega-6 long chain polyunsaturated fatty acids (LC-PUFAs), notably EPA (eicosapentaenoic acid, 20:5n-3), DHA (docosahexaenoic acid, 22:6n-3), and ARA (arachidonic acid, 20:4n-6), and their transformation into bioactive lipid mediators. In this sense, new f...
Source: Clinical Prostate Cancer - July 30, 2017 Category: Cancer & Oncology Authors: Zárate R, El Jaber-Vazdekis N, Tejera N, Pérez JA, Rodríguez C Tags: Clin Transl Med Source Type: research

Integrating phosphoproteomics into the clinical management of prostate cancer.
Abstract Phosphoproteomic analysis of tumor samples has the potential to uncover significant insights into kinase signaling networks present in late stage prostate cancer that are complementary to genomic and transcriptomic approaches. Phosphoproteomics could potentially aid drug development in clinical trial design as well as provide utility for oncologists in the personalized therapeutic management of individual cancers through identifying novel biomarkers and druggable targets. Rapid advancement of targeted mass spectrometry platforms is underway to integrate phosphoproteomic technology with genomic assays to s...
Source: Clinical Prostate Cancer - February 17, 2017 Category: Cancer & Oncology Authors: Cheng LC, Tan VM, Ganesan S, Drake JM Tags: Clin Transl Med Source Type: research

The Big 3: An Updated Overview of Colorectal, Breast, and Prostate Cancers.
This article provides a current overview of colorectal, breast, and prostate cancers. For each cancer, data related to incidence and prevalence are discussed, as well as nonmodifiable and modifiable risk factors. Information about detection and evidenced-based screening guideline recommendations is reviewed, with the most common and recent treatment modalities emphasized. Current clinical and treatment-related issues are discussed along with nursing care and implications for cancer care. Future directions for these 3 cancers are addressed also. PMID: 28189165 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 14, 2017 Category: Cancer & Oncology Authors: Gordon J, Fischer-Cartlidge E, Barton-Burke M Tags: Nurs Clin North Am Source Type: research

Prostate MR Imaging: An Update.
Abstract Improvements in prostate MR imaging techniques and the introduction of MR imaging-targeted biopsies have had central roles in prostate cancer (PCa) management. The role of MR imaging has progressed from largely staging patients with biopsy-proven PCa to detecting, characterizing, and guiding the biopsy of suspected PCa. These diagnostic advances, combined with improved therapeutic interventions, have led to a more sophisticated and individually tailored approach to patients' unique PCa profile. This review discusses the MR imaging, a standardized reporting scheme, and the role of fusion-targeted prostate ...
Source: Clinical Prostate Cancer - January 28, 2017 Category: Cancer & Oncology Authors: Shaish H, Taneja SS, Rosenkrantz AB Tags: Radiol Clin North Am Source Type: research

Diffusion-Weighted Genitourinary Imaging.
hoeny H Abstract This review article aims to provide an overview on of diffusion-weighted MR imaging (DW-MR imaging) in the urogenital tract. Compared with conventional cross-sectional imaging methods, the additional value of DW-MR imaging in the detection and further characterization of benign and malignant lesions of the kidneys, bladder, prostate, and pelvic lymph nodes is discussed as well as the role of DW-MR imaging in the evaluation of treatment response. PMID: 28126222 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 28, 2017 Category: Cancer & Oncology Authors: Maurer MH, Härmä KH, Thoeny H Tags: Radiol Clin North Am Source Type: research

Distress During Radiation Therapy: Assessment Among Patients With Breast or Prostate Cancer 
.
Distress During Radiation Therapy: Assessment Among Patients With Breast or Prostate Cancer
. Clin J Oncol Nurs. 2017 Feb 01;21(1):93-98 Authors: Stapleton SJ, Valerio TD, Astroth K, Woodhouse S Abstract BACKGROUND: Distress is regarded as the sixth vital sign in cancer care, but few studies describe distress in patients undergoing radiation therapy. 
. OBJECTIVES: The purpose of this study was to assess distress levels among patients with breast or prostate cancer undergoing radiation therapy and investigate which problems contribute to patients' distress levels. 
. METHODS: A retrosp...
Source: Clinical Prostate Cancer - January 22, 2017 Category: Cancer & Oncology Authors: Stapleton SJ, Valerio TD, Astroth K, Woodhouse S Tags: Clin J Oncol Nurs Source Type: research

Prostate cancer, PI3K, PTEN and prognosis.
Abstract Loss of function of the PTEN tumour suppressor, resulting in dysregulated activation of the phosphoinositide 3-kinase (PI3K) signalling network, is recognized as one of the most common driving events in prostate cancer development. The observed mechanisms of PTEN loss are diverse, but both homozygous and heterozygous genomic deletions including PTEN are frequent, and often accompanied by loss of detectable protein as assessed by immunohistochemistry (IHC). The occurrence of PTEN loss is highest in aggressive metastatic disease and this has driven the development of PTEN as a prognostic biomarker, either a...
Source: Clinical Prostate Cancer - January 9, 2017 Category: Cancer & Oncology Authors: Wise HM, Hermida MA, Leslie NR Tags: Clin Sci (Lond) Source Type: research

Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions.
Abstract The treatment of elderly patients with cancer is usually viewed by clinicians as a challenge, because of the age-related decline in normal organ function and the frequent concomitant administration of multiple drugs for comorbid conditions. Clinicians therefore tend not to prescribe antineoplastic agents (mainly in the case of chemotherapy) to elderly patients, with the fear of excess toxicity leading to an unfavorable cost:benefit ratio. The cutoff age defining a cancer patient as elderly is usually 70 years, but over the last 10 years clinicians have paid more attention to functional status, as evaluate...
Source: Clinical Prostate Cancer - January 7, 2017 Category: Cancer & Oncology Authors: Caffo O, Maines F, Rizzo M, Kinspergher S, Veccia A Tags: Clin Interv Aging Source Type: research

Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer.
Abstract Prostate cancer is the second most diagnosed cancer in males in the world. Plasma quantification of prostate-specific antigen substantially improved the early detection of prostate cancer, but still lacks the required specificity. Clinical management of prostate cancer needs advances in the development of new non-invasive biomarkers, ameliorating current diagnosis and prognosis and guiding therapeutic decisions. microRNAs (miRNAs) are a class of small non-coding RNAs that regulate gene expression at the post-transcriptional level. These miRNAs are expressed in the cells and are also present in cell-derive...
Source: Clinical Prostate Cancer - January 3, 2017 Category: Cancer & Oncology Authors: Valentino A, Reclusa P, Sirera R, Giallombardo M, Camps C, Pauwels P, Crispi S, Rolfo C Tags: Clin Transl Oncol Source Type: research

Monte Carlo Decision Curve Analysis Using Aggregate Data.
CONCLUSIONS: We provide a simple, easy-to-use model, which can facilitate wider use of DCA and better evaluation of diagnostic tests and predictive models that rely only on aggregate data reported in literature. This article is protected by copyright. All rights reserved. PMID: 28042671 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 1, 2017 Category: Cancer & Oncology Authors: Hozo I, Tsalatsanis A, Djulbegovic B Tags: Eur J Clin Invest Source Type: research

The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial.
CONCLUSIONS: The present study showed a significantly high PSA response compared with previous reports. Most patients tolerated the protocol treatment well, whereas hematotoxicity was often observed. PMID: 28042138 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - December 31, 2016 Category: Cancer & Oncology Authors: Tanaka N, Nishimura K, Okajima E, Ina K, Ogawa O, Nagata H, Akakura K, Fujimoto K, Gotoh M, Teramukai S, Hirao Y Tags: Jpn J Clin Oncol Source Type: research

Can Prostate Cancer Really Respond to Immunotherapy?
PMID: 28034060 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - December 31, 2016 Category: Cancer & Oncology Authors: Kim W, Fong L Tags: J Clin Oncol Source Type: research

Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial-There is No Significant Reduction in Death (Yet).
PMID: 28034067 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - December 31, 2016 Category: Cancer & Oncology Authors: Michels J Tags: J Clin Oncol Source Type: research

Does Enzalutamide Really Reduce the Risk of Progression Compared With Bicalutamide in Patients With Castration-Resistant Prostate Cancer?
ın B PMID: 28034074 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - December 31, 2016 Category: Cancer & Oncology Authors: Şendur MA, Yalçın B Tags: J Clin Oncol Source Type: research

Molecular Imaging and Precision Medicine in Prostate Cancer.
Abstract The aim of the present review is to discuss about the role of new probes for molecular imaging in the evaluation of prostate cancer (PCa). This review focuses particularly on the role of new promising radiotracers for the molecular imaging with PET/computed tomography in the detection of PCa recurrence. The role of these new imaging techniques to guide lesion-target therapies and the potential application of these molecular probes as theranostics agents is discussed. Finally, the molecular mechanisms underlying resistance to castration in PCa and the maintenance of active androgen receptor are discussed. ...
Source: Clinical Prostate Cancer - November 21, 2016 Category: Cancer & Oncology Authors: Ceci F, Fiorentino M, Castellucci P, Fanti S Tags: PET Clin Source Type: research

Depurinating estrogen-DNA adducts, generators of cancer initiation: their minimization leads to cancer prevention.
Abstract Estrogens can initiate cancer by reacting with DNA. Specific metabolites of endogenous estrogens, the catechol estrogen-3,4-quinones, react with DNA to form depurinating estrogen-DNA adducts. Loss of these adducts leaves apurinic sites in the DNA, generating mutations that can lead to the initiation of cancer. A variety of endogenous and exogenous factors can disrupt estrogen homeostasis, which is the normal balance between estrogen activating and protective enzymes. In fact, if estrogen metabolism becomes unbalanced and generates excessive catechol estrogen 3,4-quinones, formation of depurinating estroge...
Source: Clinical Prostate Cancer - March 18, 2016 Category: Cancer & Oncology Authors: Cavalieri EL, Rogan EG Tags: Clin Transl Med Source Type: research

Dynamic interplay between locus-specific DNA methylation and hydroxymethylation regulates distinct biological pathways in prostate carcinogenesis.
CONCLUSIONS: Our results indicate a distinct function for aberrant hydroxymethylation within each genomic feature in cancer, suggesting a specific and complex role for the deregulation of hydroxymethylation in tumorigenesis, similar to methylation. Subsequently, our characterization of key cellular pathways exhibiting dynamic enrichment patterns for methylation and hydroxymethylation marks may allow us to identify differentially epigenetically modified target genes implicated in prostate cancer tumorigenesis. PMID: 26981160 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 18, 2016 Category: Cancer & Oncology Authors: Kamdar SN, Ho LT, Kron KJ, Isserlin R, van der Kwast T, Zlotta AR, Fleshner NE, Bader G, Bapat B Tags: Clin Epigenetics Source Type: research

Prostate cancer: Little intraindividual heterogeneity in metastases.
PMID: 26977784 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 15, 2016 Category: Cancer & Oncology Authors: Sidaway P Tags: Nat Rev Clin Oncol Source Type: research

Tuberculous Prostatic Abscess with Prostatorectal Fistula after Intravesical Bacillus Calmette-Guérin Immunotherapy.
Tuberculous Prostatic Abscess with Prostatorectal Fistula after Intravesical Bacillus Calmette-Guérin Immunotherapy. Clin Endosc. 2016 Mar 15; Authors: Eom JH, Yoon JH, Lee SW, Kim HS, Park TY, Bang CS, Baik GH, Kim DJ Abstract Intravesical bacillus Calmette-Guérin (BCG) immunotherapy is a common treatment modality for bladder cancer after transurethral resection of a bladder tumor. This therapy is generally safe, and development of a prostatic abscess with a prostatorectal fistula after intravesical BCG immunotherapy is a very rare complication. This finding was incidentally obtained by...
Source: Clinical Prostate Cancer - March 15, 2016 Category: Cancer & Oncology Authors: Eom JH, Yoon JH, Lee SW, Kim HS, Park TY, Bang CS, Baik GH, Kim DJ Tags: Clin Endosc Source Type: research

Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.
Abstract PURPOSE: Up to 30% of patients who undergo radiation for intermediate- or high-risk localized prostate cancer relapse biochemically within 5 years. We assessed if biochemical disease-free survival (DFS) is improved by adding 6 months of androgen suppression (AS; two injections of every-3-months depot of luteinizing hormone-releasing hormone agonist) to primary radiotherapy (RT) for intermediate- or high-risk localized prostate cancer. PATIENTS AND METHODS: A total of 819 patients staged: (1) cT1b-c, with prostate-specific antigen (PSA) ≥ 10 ng/mL or Gleason ≥ 7, or (2) cT2a (International Union...
Source: Clinical Prostate Cancer - March 14, 2016 Category: Cancer & Oncology Authors: Bolla M, Maingon P, Carrie C, Villa S, Kitsios P, Poortmans PM, Sundar S, van der Steen-Banasik EM, Armstrong J, Bosset JF, Herrera FG, Pieters B, Slot A, Bahl A, Ben-Yosef R, Boehmer D, Scrase C, Renard L, Shash E, Coens C, van den Bergh AC, Collette L Tags: J Clin Oncol Source Type: research

Weighing the Addition of Androgen Suppression Therapy to Radiotherapy Dose Escalation for Intermediate-Risk Prostate Cancer.
PMID: 26976421 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 14, 2016 Category: Cancer & Oncology Authors: Pollack A, Abramowitz MC Tags: J Clin Oncol Source Type: research

68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT.
CONCLUSIONS: The sequential imaging approach designed to limit Ga-PSMA imaging to patients with negative choline scans resulted in high detection rates. Ga-PSMA-PET/CT identified sites of recurrent disease in 43.8% of the patients with negative F-choline PET/CT scans. PMID: 26975008 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 11, 2016 Category: Cancer & Oncology Authors: Bluemel C, Krebs M, Polat B, Linke F, Eiber M, Samnick S, Lapa C, Lassmann M, Riedmiller H, Czernin J, Rubello D, Bley T, Kropf S, Wester HJ, Buck AK, Herrmann K Tags: Clin Nucl Med Source Type: research

Age Bias in Time From Diagnosis Comparisons of Prostate Cancer Treatment.
CONCLUSIONS: The survival benefit apparent to prostatectomy in conventional observational cohort studies could reflect an age-related bias attributable to their use of TFD analysis. Care is warranted in the choice of timescale in observational analysis if large age differences exist between treatment cohorts. Randomized controlled trials remain the most reliable means to compare prostate cancer treatments. PMID: 26967329 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 10, 2016 Category: Cancer & Oncology Authors: Kendal WS Tags: Am J Clin Oncol Source Type: research

Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer.
CONCLUSIONS: In this report of intermediate- and high-risk prostate cancer, continuously greater rates of decline PSA for duration 1, 2 and 3 year following SBRT boost after WPRT resulted in lower PSA nadir. Also, SBRT boost after WBPT leads to favorable BCF-free survival. PMID: 26969216 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 10, 2016 Category: Cancer & Oncology Authors: Kim HJ, Phak JH, Kim WC Tags: Asia Pac J Clin Oncol Source Type: research

A prospective multicenter study of intermittent chemotherapy with docetaxel and prednisolone for castration-resistant prostate cancer.
CONCLUSIONS: Intermittent docetaxel and prednisolone therapy might be a feasible treatment option for castration-resistant prostate cancer with comparable outcome and successful chemotherapy holidays. PMID: 26962246 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 8, 2016 Category: Cancer & Oncology Authors: Narita S, Koie T, Yamada S, Orikasa K, Matsuo S, Aoki H, Ishidoya S, Hoshi S, Tsuchiya N, Ohyama C, Arai Y, Habuchi T Tags: Jpn J Clin Oncol Source Type: research

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
nock IF, Small EJ Abstract PURPOSE: Reports have suggested that metastatic site is an important predictor of overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), but these were based on a limited number of patients. We investigate the impact of site of metastases on OS of a substantial sample of men with mCRPC who received docetaxel chemotherapy in nine phase III trials. PATIENTS AND METHODS: Individual patient data from 8,820 men with mCRPC enrolled onto nine phase III trials were combined. Site of metastases was categorized as lymph node (LN) only, bone with or without ...
Source: Clinical Prostate Cancer - March 7, 2016 Category: Cancer & Oncology Authors: Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, Eisenberger MA, Fandi A, Li S, Araujo JC, Logothetis CJ, Quinn DI, Morris MJ, Higano CS, Ta Tags: J Clin Oncol Source Type: research

Impact of visceral fat volume and fat density on biochemical outcome after radical prostatectomy and postoperative radiotherapy.
CONCLUSIONS: In both univariate and multivariate analysis, patients with both a larger VAT volume and density had a better biochemical outcome. The interaction between prostate cancer aggressiveness and visceral fat volume and density needs to be further evaluated to provide a better understanding of this disease. PMID: 26943612 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 4, 2016 Category: Cancer & Oncology Authors: Zimmermann M, Delouya G, Barkati M, Campeau S, Rompotinos D, Taussky D Tags: Horm Mol Biol Clin Investig Source Type: research

CD146 promotes metastasis and predicts poor prognosis of hepatocellular carcinoma.
CONCLUSIONS: CD146 promoted metastasis of HCC cells and predicted poor prognosis of HCC patients. CD146 induced EMT, and IL-8 upregulation and STAT1 downregulation may be the potential underlying mechanism. The exact mechanism still needs further investigation. PMID: 26928402 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 3, 2016 Category: Cancer & Oncology Authors: Jiang G, Zhang L, Zhu Q, Bai D, Zhang C, Wang X Tags: J Exp Clin Cancer Res Source Type: research

Metabolic and molecular regulation of dietary polyunsaturated fatty acids on prostate cancer.
CONCLUSIONS AND CLINICAL RELEVANCE: This study suggests that suppression of cell viability by fish oil is independent of fatty acid synthase and fish oil regulates prostate cancer cells through activation of other pathways depending upon length of exposure to fish oil. PMID: 26929070 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 1, 2016 Category: Cancer & Oncology Authors: Zhao H, Pflug BR, Lai X, Wang M Tags: Proteomics Clin Appl Source Type: research

Novel strategies for molecular targeting to cancer.
Abstract This editorial draws attention to the work published by CEPP in 2014-2015 on mechanisms underlying cancer drug resistance, invasion and metastasis. Genetic, genomic and immunological changes in platinum drug resistance and new drug candidates for cancer metastasis are highlighted. Attention is paid to the Epimedium plant drug icariin in glioblastoma invasion, the plant Avicennia marina bioactive compound Naphtho[1,2-b]furan-4,5-dione in breast cancer metastasis, the PI3K inhibitor BEZ235 in colon cancer stem cells, the histone methyltransferase EZH1 inhibitor GSK343 in cervical cancer, and vitamin D3 in p...
Source: Clinical Prostate Cancer - February 19, 2016 Category: Cancer & Oncology Authors: Liu JP Tags: Clin Exp Pharmacol Physiol Source Type: research

Status and Interrelationship of Zinc, Copper, Iron, Calcium and Selenium in Prostate Cancer.
This study was aimed to detect differential changes and mutual correlations of selected trace elements in prostate cancer tissue versus benign prostatic hyperplasia tissue. Zinc, copper, iron, calcium and selenium were analysed in histologically proven 15 prostate cancer tissues and 15 benign prostatic hyperplasia tissues using atomic absorption spectrophotometer. Unpaired two tailed t test/Mann-Whitney U test and Pearson correlation coefficient were used to compare the level of trace elements, elemental ratios and their interrelations. As compared to benign prostatic tissue, malignant prostatic tissue had significantly lo...
Source: Clinical Prostate Cancer - February 10, 2016 Category: Cancer & Oncology Authors: Singh BP, Dwivedi S, Dhakad U, Murthy RC, Choubey VK, Goel A, Sankhwar SN Tags: Indian J Clin Biochem Source Type: research

Protein Kinase D Enzymes as Regulators of EMT and Cancer Cell Invasion.
Abstract The Protein Kinase D (PKD) isoforms PKD1, PKD2, and PKD3 are effectors of the novel Protein Kinase Cs (nPKCs) and diacylglycerol (DAG). PKDs impact diverse biological processes like protein transport, cell migration, proliferation, epithelial to mesenchymal transition (EMT) and apoptosis. PKDs however, have distinct effects on these functions. While PKD1 blocks EMT and cell migration, PKD2 and PKD3 tend to drive both processes. Given the importance of EMT and cell migration to the initiation and progression of various malignancies, abnormal expression of PKDs has been reported in multiple types of cancers...
Source: Clinical Prostate Cancer - February 9, 2016 Category: Cancer & Oncology Authors: Durand N, Borges S, Storz P Tags: J Clin Med Source Type: research

Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer.
CONCLUSIONS: WPRT followed by SBRT boost using Cyberknife in intermediate- and high-risk prostate cancer is feasible with minimal toxicity and encouraging BCF-free survival. PMID: 26846353 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 5, 2016 Category: Cancer & Oncology Authors: Kim HJ, Phak JH, Kim WC Tags: Asia Pac J Clin Oncol Source Type: research

Role of EMT in Metastasis and Therapy Resistance.
Abstract Epithelial-mesenchymal transition (EMT) is a complex molecular program that regulates changes in cell morphology and function during embryogenesis and tissue development. EMT also contributes to tumor progression and metastasis. Cells undergoing EMT expand out of and degrade the surrounding microenvironment to subsequently migrate from the primary site. The mesenchymal phenotype observed in fibroblasts is specifically important based on the expression of smooth muscle actin (α-SMA), fibroblast growth factor (FGF), fibroblast-specific protein-1 (FSP1), and collagen to enhance EMT. Although EMT is not...
Source: Clinical Prostate Cancer - February 3, 2016 Category: Cancer & Oncology Authors: Smith BN, Bhowmick NA Tags: J Clin Med Source Type: research

Prostate cancer: Personalized risk - stratified screening or abandoning it altogether?
PMID: 26831183 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 2, 2016 Category: Cancer & Oncology Authors: Carlsson SV, Kattan MW Tags: Nat Rev Clin Oncol Source Type: research

Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study.
Abstract PURPOSE: Cardiovascular diseases (CVDs), including ischemic heart disease, stroke, and heart failure, are well-established late effects of therapy in survivors of childhood and young adult (
Source: Clinical Prostate Cancer - February 1, 2016 Category: Cancer & Oncology Authors: Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK, Douglas PS, Bhatia S, Chao C Tags: J Clin Oncol Source Type: research

Role of Multiparametric MR Imaging in Malignancies of the Urogenital Tract.
This article focuses on mpMRI in the evaluation of urogenital tract malignancies by first reviewing technical aspects and then discussing its potential clinical role. This includes insight into histologic subtyping and grading of renal cell carcinoma and assessment of tumor response to targeted therapies. The clinical utility of mpMRI in the staging and grading of ureteral and bladder tumors is presented. Finally, the evolving role of mpMRI in prostate cancer is discussed. PMID: 26613881 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - December 2, 2015 Category: Cancer & Oncology Authors: Diaz de Leon A, Costa D, Pedrosa I Tags: Magn Reson Imaging Clin N Am Source Type: research

Management of Prostate Cancer in the Elderly.
Abstract The impact of localized prostate cancer in the elderly depends on disease aggressiveness and life expectancy. In men with localized prostate cancer, those with low-risk disease or a shorter life expectancy should be managed expectantly, whereas those with long life expectancy or more aggressive disease may benefit from curative treatment. Comorbidity and quality-of-life concerns are key considerations during the selection of therapeutic modalities in the elderly in localized and metastatic settings. A variety of new agents have changed the therapeutic landscape in castrate-resistant prostate cancer, but t...
Source: Clinical Prostate Cancer - December 2, 2015 Category: Cancer & Oncology Authors: Tay KJ, Moul JW, Armstrong AJ Tags: Clin Geriatr Med Source Type: research

Pathologic findings in patients with targeted magnetic resonance imaging-guided prostate needle core biopsies.
Abstract In contrast to the routine (non-targeted) sampling approach of transrectal ultrasound guided biopsies (TRUS-GB), targeted magnetic resonance imaging-guided biopsies (TMRI-GB) target regions of the prostate suspicious for prostate cancer (PCa), based on findings on multiparametric MRI. We sought to examine the pathologic findings identified on TMRI-GB, due to the fact that there are limited studies on this in the Pathology literature. A search was made through our Urologic Pathology files for prostate needle core biopsies that were obtained via TMRI-GB. Forty-six patients were identified. Mean patient (PT)...
Source: Clinical Prostate Cancer - December 2, 2015 Category: Cancer & Oncology Authors: Geller RL, Nour SG, Osunkoya AO Tags: Int J Clin Exp Pathol Source Type: research

MSH3 rs26279 polymorphism increases cancer risk: a meta-analysis.
Abstract Previous studies have investigated the association of mutS homolog 3 (MSH3) rs26279 G> A polymorphism with the risk of different types of cancers including colorectal cancer, breast cancer, prostate cancer, bladder cancer, thyroid cancer, ovarian cancer and oesophageal cancer. However, its association with cancer remains conflicting. We performed a comprehensive meta-analysis to derive a more precise estimation of the relationship between MSH3 rs26279 G> A polymorphism and cancer susceptibility. Systematically searching the PubMed and EMBASE databases yielded 11 publications with 12 studies of 3282 ...
Source: Clinical Prostate Cancer - December 2, 2015 Category: Cancer & Oncology Authors: Miao HK, Chen LP, Cai DP, Kong WJ, Xiao L, Lin J Tags: Int J Clin Exp Pathol Source Type: research

Beta-3 adrenergic receptors could be significant factors for overactive bladder-related symptoms.
Abstract The treatment failure often happens in overactive bladder (OAB) partly owing to its unknown pathogenesis. The purpose of this study is to find significant receptors or biological markers for OAB-related symptoms for establishment of potential order-made therapeutic strategies. The overactive bladder symptom scores (OABSS) and international prostate symptom scores (IPSS)/quality of life (QOL) were questioned in all the 18 patients with OAB diagnosis. Their bladder mucosal tissues were taken from the random biopsy of bladder cancer suspected patients without any finding such as inflammation or carcinoma in ...
Source: Clinical Prostate Cancer - December 2, 2015 Category: Cancer & Oncology Authors: Yamamichi F, Shigemura K, Behnsawy HM, Yamashita M, Shirakawa T, Fujisawa M Tags: Int J Clin Exp Pathol Source Type: research

Molecular Updates in Prostate Cancer.
Abstract A wide array of molecular markers and genomic signatures, reviewed in this article, may soon be used as adjuncts to currently established screening strategies, prognostic parameters, and early detection markers. Markers of genetic susceptibility to PCA, recurrent epigenetic and genetic alterations, including ETS gene fusions, PTEN alterations, and urine-based early detection marker PCA3, are discussed. Impact of recent genome-wide assessment on our understanding of key pathways of PCA development and progression and their potential clinical implications are highlighted. PMID: 26612215 [PubMed - in pr...
Source: Clinical Prostate Cancer - November 29, 2015 Category: Cancer & Oncology Authors: Netto GJ Tags: Surg Pathol Clin Source Type: research

Active Surveillance: Pathologic and Clinical Variables Associated with Outcome.
Abstract Over the past 10 years, active surveillance has emerged as a primary management option for men diagnosed with low-risk prostate cancer. Given the morbidity associated with curative treatment, active surveillance maintains quality of life for men whose disease may never become symptomatic. In order to confidently and safely offer this approach to as many patients as possible, improved metrics are needed to fully assess risk. While pathologic and clinical variables currently help determine whether active surveillance is a reasonable approach, emerging biomarkers and imaging technologies demonstrate promise ...
Source: Clinical Prostate Cancer - November 29, 2015 Category: Cancer & Oncology Authors: Pomerantz M Tags: Surg Pathol Clin Source Type: research

Updates in Benign Lesions of the Genitourinary Tract.
Abstract The genitourinary tract is a common site for new cancer diagnosis, particularly for men. Therefore, cancer-containing specimens are very common in surgical pathology practice. However, many benign neoplasms and nonneoplastic, reactive, and inflammatory processes in the genitourinary tract may mimic or cause differential diagnostic challenges with malignancies. Emerging clinicopathologic, immunohistochemical, and molecular characteristics have shed light on the pathogenesis and differential diagnosis of these lesions. This review addresses differential diagnostic challenges related to benign genitouri...
Source: Clinical Prostate Cancer - November 29, 2015 Category: Cancer & Oncology Authors: Arias-Stella JA, Williamson SR Tags: Surg Pathol Clin Source Type: research